Inclusion Criteria:

          -  Histologic documentation: newly diagnosed World Health Organization (WHO) grade IV
             intracranial glioblastoma or gliosarcoma; GBM with oligodendroglial features are NOT
             PERMITTED in this study if they are 1p19q codeleted; sites submitting GBM with
             oligodendroglial features will be asked to provide results of 1p/19q codeletion status

          -  Sufficient tissue available for central pathology review and MGMT methylation status
             evaluation

          -  Patients who have had a local MGMT testing that is unmethylated are not allowed to
             participate

          -  Tumor MGMT promoter hypermethylation determined by central testing at MD Anderson

          -  Confirmation by central pathology review of WHO grade IV glioblastoma or gliosarcoma

          -  Absolute neutrophil count (ANC) >= 1500 cells/mm^3 (within 14 days prior to study
             registration)

          -  Platelets >= 100,000 cells/mm^3 (within 14 days prior to study registration)

          -  Creatinine =< 1.5 x upper limit of normal (ULN) (within 14 days prior to study
             registration)

          -  Bilirubin =< 1.5 x ULN (within 14 days prior to study registration; unless patient has
             Gilbert's disease)

          -  Alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to study registration)

          -  Aspartate aminotransferase (AST) =< 3 x ULN (within 14 days prior to study
             registration)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2

          -  Measurable disease or non-measurable disease; extent of resection: patients with
             complete resection, partial resection, or biopsy are eligible

          -  Progression: patients deemed to have progressive disease based on clinical
             deterioration after chemoradiation or radiographic progression outside of the
             radiation field are not eligible; patients deemed to have pseudoprogression are
             eligible

          -  Prior treatment:

               -  Must have completed standard radiotherapy and concomitant TMZ therapy as defined
                  and determined by the study oncologist

               -  Besides concomitant TMZ with radiation, no other therapy (neo-adjuvant or
                  adjuvant) can be given prior to study registration, including chemotherapy (also
                  including Gliadel/carmustine [BCNU] wafers), biologics, immunotherapy, radiation
                  therapy; the only exception is the Optune device (NovoTTF-100A), which may be
                  started any time after end of radiation therapy up through the initiation of
                  Cycle 1; intent to use Optune must be declared at registration for stratification

               -  No prior allogeneic bone marrow transplant or double umbilical cord blood
                  transplantation

          -  Not pregnant and not nursing; females of childbearing potential must have negative
             urine or serum pregnancy test within 7 days of registration but before start of
             treatment; a female of childbearing potential is a sexually mature female who:

               -  Has not undergone a hysterectomy or bilateral oophorectomy; or

               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
                  has had menses at any time in the preceding 12 consecutive months)

          -  Concomitant medications: patients receiving anticoagulation should be on stable dose 2
             weeks prior to registration

          -  Comorbid conditions: patients are unable to participate due to the following:

               -  Generalized or partial seizure disorder that is uncontrolled at the time of
                  registration; the definition of controlled generalized seizures is patients must
                  be on a stable dose of anti-seizure medication and without generalized seizures
                  for at least 10 days prior to registration; the definition of controlled partial
                  seizures is patients must be on a stable dose of anti-seizure medication for at
                  least 10 days prior to registration; patients with occasional breakthrough
                  partial seizures are allowed at treating physician's discretion

               -  Grade 3 or 4 thromboembolic disease within 6 months (mo) of registration

               -  Known history of prolonged QT syndrome

          -  No history of major surgery =< 14 days prior to registration

          -  Patients must have adequate organ and marrow function measured within 28 days prior to
             administration of ABT-888 as defined below:

               -  >= 10.0 g/dL hemoglobin (Hb) with no blood transfusion in the past 28 days

          -  No Patients with treatment-related acute myeloid leukemia (AML)
             (t-AML)/myelodysplastic syndrome (MDS) or with features suggestive of AML/MDS